Fig. 5
From: AMPAkines potentiate the corticostriatal pathway to reduce acute and chronic pain
AMPAkine in the NAc partially reconstitutes the anti-nociceptive effects of PL on chronic neuropathic pain. a Schematic of the SNI model. b SNI treatment induces mechanical allodynia, compared with SHAM-treated rats. SNI group, n = 12; SHAM group, n = 13; ****p < 0.0001, Two-way ANOVA with repeated measures and Bonferroni’s multiple pair-wise comparisons. c SNI treatment induces cold allodynia, compared with SHAM-treated rats. SNI group, n = 12; SHAM group, n = 13; ****p < 0.0001, Two-way ANOVA with repeated measures and Bonferroni’s multiple pair-wise comparisons. d Optogenetic activation of the PL decreased mechanical allodynia in SNI-treated rats; AMPAkine infusion in the NAc decreased mechanical allodynia in YFP rats but not ChR2 rats. ChR2 group, n = 6; YFP group, n = 6; ChR2 vs YFP, after AMPAkine infusion (****p < 0.0001), after saline infusion (****p < 0.0001); AMPAkine vs saline, in ChR2 rats (p > 0.9999), in YFP rats (***p = 0.0002); Two-way ANOVA with repeated measures and Bonferroni’s multiple pair-wise comparisons. e Activation of the PL decreased cold allodynia in SNI-treated rats; AMPAkine infusion decreased cold allodynia in YFP but not ChR2 rats. ChR2 group, n = 6; YFP group, n = 6; ChR2 vs YFP, after AMPAkine infusion (*p = 0.0364), after saline infusion (****p < 0.0001); AMPAkine vs saline, in ChR2 rats (p > 0.9999), in YFP rats (****p < 0.0001); Two-way ANOVA with repeated measures and Bonferroni’s multiple pair-wise comparisons